Retractable Technologies, Inc.

What they do

The company manufactures and markets safety medical products, predominantly retractable syringes and needles, under the VanishPoint, Patient Safe and EasyPoint brands. It operates a manufacturing facility in Little Elm, Texas and also sources finished goods from manufacturers in China. Products are sold nationally and internationally through numerous distributors, with syringes suited to vaccine administration.

Revenue drivers

• VanishPoint syringes — Syringes were 65.1% of 2025 sales and 83.8% of sales in the first six months of 2026; these retractable devices are the dominant revenue source.
• EasyPoint products — EasyPoint needles accounted for 31.2% of 2025 sales but only 11.4% of sales in the first six months of 2026, indicating a declining contribution.
• Other products — IV safety catheters and blood collection products represented 3.7% of 2025 total product sales and 4.8% of sales in the first six months of 2026.

Recent performance

Annual revenue fell from $188.4M in 2021 to $33.0M in 2024 before recovering to $38.3M in 2025. Net income was negative each year from 2023 through 2025, at -$7.0M, -$11.9M and -$12.6M respectively, with diluted EPS of -$0.24, -$0.40 and -$0.43. Operating cash flow was $2.8M in 2023 but turned negative at -$11.6M in 2024 and -$7.1M in 2025. Quarterly revenue declined from $10.1M in the quarter ended 2025-09-30 to $7.2M in each of the quarters ended 2026-03-31 and 2026-06-30. At 2026-06-30 the company reported $2.6M of cash and equivalents against $68.8M of total liabilities.

Strategy

The company is shifting a larger portion of 1mL, 3mL and EasyPoint needle manufacturing to its domestic facility to reduce tariff exposure, while continuing strategic ordering from Chinese suppliers. It increased domestic vaccine-related manufacturing capacity, funded in part by an $81.0M Technology Investment Agreement with the Department of Defense on behalf of BARDA, which runs until June 30, 2030 and requires equipment maintenance, capacity availability and U.S. government preference in a public health emergency. Management expects international sales of VanishPoint syringes and EasyPoint needles to increase in the second half of 2026 following certification under the European Union Medical Device Regulation 2017/745. It is implementing inclusion of that certification on packaging and operational documents.

Risks

• China tariff exposure — As of August 1, 2026 the prevailing tariff rate on most syringe and needle products imported from China was 112.5%, and 57.6% of units manufactured in the first six months of 2026 came from China.
• Sourcing concentration — Some products are sourced exclusively from China, so continued or higher tariffs could impair the ability to obtain finished goods, raw materials and components.
• Liquidity — Cash and equivalents were $2.6M at 2026-06-30 against $68.8M of total liabilities, with negative operating cash flow of $7.1M in 2025.
• Tariff refund repayment — Approximately $1.3 million in tariff refunds received in the first half of 2026 were processed incorrectly and are subject to potential repayment, and are recorded as a liability.

Outlook

Management expects international sales of VanishPoint syringes and EasyPoint needles to increase in the second half of 2026 after EU MDR certification. It states that tariffs may continue to have a material impact on sourcing and on results of operations and financial position. Tariff rates remain uncertain and subject to further change.